Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property
Open accessThe DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Abstract
PARP1 trapping at DNA lesion by pharmacological inhibitors has been exploited in several cancers exhibiting defects in DNA repair mechanisms. PARP1 hyperactivation is involved in therapeutic resistance in multiple cancers. The role of PARP1 in cervical cancer (CC) resistance and implication of PARP inhibitor is yet to be elucidated. Our data demonstrates significantly higher expression of PARP1 in primary cervical tumors and CC cell lines SiHa and ME180. Upon cisplatin treatment CC cells display significant overexpression of PARP1 and its hyperactivation. PARP inhibitor olaparib shows significant anti-proliferative effect on CC cells and drive loss of clonogenic survival and enhanced cell death in combination with cisplatin. PARP inhibited cells show delay in resolution of γH2A.X foci and prolonged late S and G2-M phase arrest resulting in apoptosis. Further, PARP inhibition disrupts the localization of base excision repair (BER) effector XRCC1 and non-homologous end joining (NHEJ) proteins Ku80 and XRCC4. Due to disrupted relocation of repair factors, cisplatin induced stalled replication forks collapse and convert into double strand breaks (DSBs). Interestingly, PARP inhibition also shows anti-migratory and anti-invasive properties in CC cells, increases anchorage independent cell death and induces anoikis. Collectively, our data demonstrates therapeutic potential of PARP inhibitor in cervical cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Figure 7 PARP1 inhibition delayed DNA repair and leads to prolonged cell cycle arrest at G2/M. (A) Both the cell lines SiHa and ME180 were treated with 10 µM cisplatin and/or olaparib for 24 hrs. After 24 hrs drug was removed (DR0) and fresh drug free media was added. Cells were cultured further and γH2A.X foci were observed very 24 hr till 10 days post drug removal (DR0 to DR10). Cells with >20 γH2A.X foci to 0 foci were counted in blind fashion and at least 200 cells per group in several different 60× objective fields were acquired. Quantitative plot displaying distribution of γH2A.X foci in three treatment groups in both the cell lines. [Time point DR3, frequency of cells with more than 20 foci per cell in SiHa; cisplatin vs. cisplatin + olaparib *p = 0.0467, at DR4; cisplatin vs. cisplatin + olaparib *p = 0.0268, at DR5; cisplatin vs. cisplatin + olaparib **p = 0.0060 and frequency of cells with more than 20 foci per cell in ME180 at DR3; cisplatin vs. cisplatin + olaparib *p = 0.0390, at DR4; cisplatin vs. cisplatin + olaparib *p = 0.041, at DR5; cisplatin vs. cisplatin + olaparib **p = 0.0024]. (B) Both the cell lines SiHa and ME180 were treated as indicated and cell were stained with FITC tagged anti γH2A.X & co-stained with PI and analysis was done using FACS for DNA damage in each cell cycle phases. Graph showing the percentage of cells with γH2A.X foci in SiHa and ME180 cell lines. PARP1 inhibition in cisplatin treated cells shows significant accumulation of DNA damage in late S and G2/M phase compared to G1. (C) Graph showing frequency of γH2A.X foci resolution in PARP1 silenced and control counterpart after cisplatin treatment. PARP1 silenced cells displayed significant delay in γH2A.X foci resolution after drug removal. (D) Similarly, PARP inhibition along with cisplatin treatment for 48 hrs shows significant & prolonged G2/M and late S phase arrest in both the cell lines after drug removal as in previous experiments.](https://figures.cochat.ai/paper-figures/eb3a147c582147ea983ae614c278bd55/olaparib-modulates-dna-repair-efficiency-sensitizes-cervical-cancer-cells-to-figure-7.jpg)



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Mechanistic studies indicate that platinum/PARPi synergy is associated with sustained DNA double-strand breaks (DSBs) leading to a significantly marked increase in apoptosis [49, 50].”
From Advances in platinum-based cancer therapy: overcoming platinum resistance through rational combinatorial strategies (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Clonogenic assay of cells in vitro
Franken, N. A. P., Rodermond, H. M., Stap, J., Haveman, J., & van Bree, C. (2006) · Nature Protocols · doi:10.1038/nprot.2006.339 · Cited by 4,188
Molecular mechanisms of cisplatin resistance
Galluzzi, L., Senovilla, L., Vitale, I., Michels, J., Martins, I., Kepp, O., Castedo, M., & Kroemer, G. (2012) · Oncogene · doi:10.1038/onc.2011.384 · Cited by 2,760
Audeh, M. W., Carmichael, J., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., Weitzel, J. N., Oaknin, A., Loman, N., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60893-8 · Cited by 2,279
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J., Takeda, S., & Pommier, Y. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,192
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Ledermann, J., Harter, P., Gourley, C., Friedlander, M., Vergote, I., Rustin, G., Scott, C., Meier, W., Shapira-Frommer, R., Safra, T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105535 · Cited by 1,883 · cited 1×
“1038/s41598-017-13232-3 of cell migration and invasion, cells were stained with CFSE [(5(6)-Carboxyfluorescein N-hydroxysuccinimidyl ester)] stain and migration and invasion assay was performed.”
Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions
d'AMOURS, D., DESNOYERS, S., d'SILVA, I., & POIRIER, G. G. (1999) · Biochemical Journal · doi:10.1042/bj3420249 · Cited by 1,815
Tutt, A., Robson, M., Garber, J. E., Domchek, S. M., Audeh, M. W., Weitzel, J. N., Friedlander, M., Arun, B., Loman, N., Schmutzler, R. K., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60892-6 · Cited by 1,655
McCabe, N., Turner, N. C., Lord, C. J., Kluzek, K., Białkowska, A., Swift, S., Giavara, S., O'Connor, M. J., Tutt, A. N., Zdzienicka, M. Z., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0140 · Cited by 1,310
DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis
Roos, W. P., & Kaina, B. (2013) · Cancer Letters · doi:10.1016/j.canlet.2012.01.007 · Cited by 879
Cited by
PARP Inhibitors in Cancer Diagnosis and Therapy
Chan, C. Y., Tan, K. V., & Cornelissen, B. T. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2766 · Cited by 114
“This trapping leads to DSB formation by stalling and collapsing replication forks (15) or accelerating fork elongation (3).”
BackgroundCurrent Treatment for Cervical Cancer: An Update
Sharma, S., Deep, A., & Sharma, A. K. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200224093301 · Cited by 113
Exosome-packaged miR-1246 contributes to bystander DNA damage by targeting LIG4
Mo, L., Song, M. S., Huang, Q.-H., Guan, H., Liu, X., Xie, D.-F., Huang, B., Huang, R., & Zhou, P. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0192-9 · Cited by 102
Penninckx, S., Pariset, E., Cekanaviciute, E., & Costes, S. V. (2021) · NAR Cancer · doi:10.1093/narcan/zcab046 · Cited by 110
Schoonen, P. M., Kok, Y. P., Wierenga, E., Bakker, B., Foijer, F., Spierings, D. C. J., & van Vugt, M. A. T. M. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12573 · Cited by 81
Metadata
- Authors
- Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G.
- Affiliations
- Banaras Hindu University (IN)
- Institute of Medical Sciences (IN)
- Corresponding author
- Narayan, Gopeshwar
- ORCID
- Venue
- Scientific Reports
- Published
- 2017-10-09
- Volume
- 7
- Issue
- 1
- Pages
- 12876-12876
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5634505
- OpenAlex
- W2762572114
- Cited by
- 84
- References
- 64
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 11 · 2023: 8 · 2022: 14 · 2021: 9 · 2020: 14 · 2019: 10 · 2018: 3 · 2017: 1
- FWCI
- 3.38
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › DNA Repair Mechanisms
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Keywords
- olaparib, PARP1, cervical cancer, cisplatin, PARP inhibitors, DNA repair, base excision repair, non-homologous end joining, replication fork collapse, DNA double-strand breaks, apoptosis, cell migration and invasion, anoikis, treatment resistance
- MeSH terms
- Poly(ADP-ribose) Polymerase Inhibitors, Poly (ADP-Ribose) Polymerase-1, Uterine Cervical Neoplasms, Cisplatin, DNA Repair, DNA Replication, Female, Humans, Neoplasm Metastasis, Nuclear Proteins, Phthalazines, Piperazines, Apoptosis, Gene Silencing, Cell Line, Tumor, DNA Breaks, Double-Stranded, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. https://app.cochat.ai/papers/10.1038/s41598-017-13232-3
- The paper
- Prasad, C. B., Prasad, S. B., Yadav, S. S., Pandey, L. K., Singh, S., Pradhan, S., & Narayan, G. (2017). Olaparib modulates DNA repair efficiency, sensitizes cervical cancer cells to cisplatin and exhibits anti-metastatic property. Scientific Reports. https://doi.org/10.1038/s41598-017-13232-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.